The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于$775,114 交易量
2026-03-31
July 31
50%
June 30
1%
December 31
24%
$775,114 交易量
July 31
$0 交易量
50%
June 30
$342,494 交易量
1%
December 31
$167,738 交易量
24%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
市场开放时间： Feb 7, 2026, 5:04 PM ET
交易量
$775,114结束日期
2026-03-31市场开放时间
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
交易量
$775,114结束日期
2026-03-31市场开放时间
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题